SPPI
Spectrum Pharmaceuticals, Inc.
Set alert
1.03 0.00 0.00%
0.9716 Day range 1.06
52-week range unavailable
- Open
- 1.02
- Prev close
- 1.03
- Mkt cap
- 195.95M
- Vol
- 4.85M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.9716
- High
- 1.06
- Forward P/E
- 7.34
- Beta
- 2.14
- Short ratio
- 2.69
- Inst. own
- 22.70%
- Dividend
- 0.00
- Ex-div date
- Dec 17, 2012
- Earnings
- Aug 10, 2023
- 50-d avg
- 1.08
- 200-d avg
- 0.71255
- 1y target
- 1.26
Key statistics
- Market cap
- 195.95M
- Enterprise value
- 168.20M
- Trailing P/E
- 0.00
- Forward P/E
- 7.34
- PEG ratio
- 0.00
- Price / sales
- 7.62
- Price / book
- 7.23
- EPS (TTM)
- -0.36
- Beta
- 2.14
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -252.50%
- Revenue (TTM)
- 25.73M
- Revenue growth
- 0.00%
- Free cash flow
- -78.77M
- Total cash
- 56.14M
- Total debt
- 30.47M
- Return on equity
- -165.02%
- Shares outstanding
- 205.25M
- Short % of float
- 1.61%
- 50-day average
- 1.08
- 200-day average
- 0.71255
Analyst view
Consensus: hold
Hold
Price target (mean) 1.26 +22.9% upside
Now 1.03
- Target (low)
- 1.14
- Target (mean)
- 1.26
- Target (high)
- 1.50
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 10, 2023
Expected Aug 10, 2023. Consensus EPS estimate -0.03.
Financials — quick view
SPPI Revenue — quarterly 15.62M
SPPI Net income — quarterly -5.01M
SPPI EPS — quarterly -0.02
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 10, 2023 | Jun 1, 2023 | -0.04 | — | — | — |
| May 9, 2023 | Mar 1, 2023 | -0.05 | — | — | — |
| Mar 22, 2023 | Dec 1, 2022 | -0.09 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | -0.15 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -0.16 | — | — | — |
| May 12, 2022 | Mar 1, 2022 | -0.18 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 26, 2023 | HC Wainwright & Co. | reit | Neutral | Neutral |
| May 15, 2023 | Jefferies | down | Buy | Hold |
| Apr 26, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Apr 26, 2023 | JMP Securities | down | Market Outperform | Market Perform |
| Feb 6, 2023 | JMP Securities | reit | — | Market Outperform |
| Feb 3, 2023 | Cantor Fitzgerald | main | — | Neutral |
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sppirx.com
News
- Kaplan Fox & Kilsheimer LLP Announces Proposed Class Action Settlement on Behalf of all Persons and Entities that Purchased the Common Stock of Spectrum Pharmaceuticals, Inc.
- NanoViricides advances Phase 2 trials for broad-spectrum antiviral NV-378 in $17B market: analysts
- Artisan Therapeutics and Tulex Pharmaceuticals Announce Positive Phase 2a Results for ART-501, a Novel Oral Liquid Extended-Release Formulation for Autism Spectrum Disorder
- NanoViricides raises cash, moves broad-spectrum antiviral NV-387 into Phase II trials
- SPECTRUM FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Before September 24th
- Spectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: FINAL DEADLINE in Securities Lawsuit– Hagens Berman
- CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025
- SPPI FINAL DEADLINE: ROSEN, TOP RANKED INVESTOR RIGHTS COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important September 24 Deadline in Securities Class Action – SPPI
- SPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
- SPPI Deadline: Rosen Law Firm Urges Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Your note
Sign in to keep a note on SPPI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ASHTON WILLIAM L | Director | Stock Award(Grant) | Aug 30, 2022 | 67,660 |
| BRADRICK BRITTANY K. | Director | Stock Award(Grant) | Aug 30, 2022 | 27,380 |
| BRENNAN NORA | Chief Financial Officer | Sale | May 25, 2023 | 567,828 |
| FISCHER SETH H Z | Director | Stock Award(Grant) | Aug 30, 2022 | 54,066 |
| LEBEL FRANCOIS | Officer | Sale | Jun 22, 2022 | 652,016 |
| LIM JUHYUN | Director | Stock Award(Grant) | Aug 30, 2022 | 29,759 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.14% | 16,700,000 | 15.94M | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 4.28% | 8,777,670 | 8.38M | Mar 30, 2023 |
| Acadian Asset Management. LLC | 1.81% | 3,712,411 | 3.54M | Mar 30, 2023 |
| Blackrock Inc. | 1.68% | 3,448,478 | 3.29M | Mar 30, 2023 |
| Geode Capital Management, LLC | 0.86% | 1,757,437 | 1.68M | Mar 30, 2023 |
| Morgan Stanley | 0.56% | 1,146,119 | 1.09M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.61% | 5,348,837 | 5.11M | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 1.11% | 2,285,849 | 2.18M | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.44% | 895,733 | 855.16K | Feb 27, 2023 |
| Vanguard Variable Insurance Fund-Small Company Growth | 0.23% | 475,988 | 454.43K | Dec 30, 2022 |
| Fidelity Total Market Index Fund | 0.16% | 326,441 | 311.65K | Feb 27, 2023 |
| Fidelity Series Total Market Index Fund | 0.10% | 210,764 | 201.22K | Feb 27, 2023 |